# Episurf > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/episurfb). ## Overview Episurf Medical is a Swedish medical technology company focused on patient-specific orthopedic implants and surgical planning tools for focal cartilage damage in joints. Its core platform centers on the Episealer® implant family and the Epioscopy® image-analysis workflow, with commercial activity concentrated in Europe and selected international markets. ## Products & services • Episealer® patient-specific joint implants • Epioscopy® image analysis and planning • Orthopedic treatment solutions for cartilage lesions • Clinical evidence and surgeon support services - **Patient-specific implants** (70%) — Custom orthopedic implants designed for focal cartilage and bone lesions in joints. - **Pre-operative imaging and planning** (15%) — Image analysis and workflow tools used to design and fit patient-specific implants. - **Clinical and surgeon support** (15%) — Clinical evidence generation, advisory support, and implementation assistance for surgeons. - Episealer® patient-specific joint implants - Epioscopy® image analysis and planning - Orthopedic treatment solutions for cartilage lesions - Clinical evidence and surgeon support services ## Customers Episurf sells primarily to orthopedic surgeons, hospitals, and specialist clinics that treat cartilage damage in the knee and ankle. These buyers use the company’s patient-specific solutions to address focal lesions in patients who need joint-preserving treatment options and a faster return to activity. - **Orthopedic surgeons** (primary) — Buy Episealer-based treatment solutions and planning tools to treat focal cartilage lesions. - **Hospitals and specialist clinics** (primary) — Purchase the implants and related workflow for joint-preserving orthopedic procedures. - **Key opinion leaders and clinical centers** (secondary) — Adopt and evaluate the technology, helping build clinical evidence and market credibility. - **Payers and reimbursement stakeholders** (secondary) — Influence adoption by determining whether the treatment is reimbursed in each market. - Orthopedic surgeons seeking patient-specific cartilage repair solutions - Hospitals and clinics treating knee and ankle joint lesions - KOLs and clinical centers that help validate the technology - Healthcare systems that require reimbursement support and evidence ## Geography Episurf is headquartered in Sweden and has focused commercialization in Europe, including the Nordics, Germany, the UK, Switzerland, Benelux, and other EU markets. The company also has presence in the United States and selected Middle Eastern countries, but reported sales in some of these regions remain limited. - Headquartered in Sweden with a Nordic operating base - Priority commercial markets include Germany, UK, Nordics, Switzerland, and Benelux - Presence in the United States supports future market expansion - Limited sales presence in parts of the Middle East adds geographic reach ## Strategy Episurf’s strategy is built around clinical evidence, surgeon adoption, reimbursement access, and manufacturing capability for its patient-specific implant platform. The company aims to expand its installed user base and strengthen the clinical and economic case for Episealer® in prioritized markets. - **Clinical evidence generation** (short-term) — Surgeons and payers need proof of outcomes before adopting a new implant platform. - **Market access and reimbursement** (medium-term) — Coverage decisions determine whether the products can be used broadly in each market. - **Surgeon and KOL adoption** (medium-term) — A larger user base improves credibility and supports repeat utilization. - **Manufacturing and product enablement** (long-term) — Patient-specific implants require reliable production and delivery to support commercialization. - Build clinical and health-economic evidence for treatment adoption - Expand the base of orthopedic surgeons and KOLs using the platform - Secure reimbursement to improve market access and utilization - Maintain production capability that supports patient-specific manufacturing ## Risks Episurf’s business depends on regulatory approvals, clinical outcomes, reimbursement decisions, and intellectual property protection, all of which can delay adoption or limit market access. As a medical device company with patient-specific manufacturing, it also faces execution risk around production, partner dependence, cybersecurity, and broader geopolitical or supply-chain disruptions. - **Regulatory approval risk** [high] — The company must obtain approvals before selling in many markets, which can delay commercialization. - **Clinical evidence and adoption risk** [high] — Surgeons and payers may not adopt the technology without strong outcomes data. - **Reimbursement risk** [high] — Coverage decisions directly affect whether hospitals and surgeons can use the products economically. - **Intellectual property risk** [medium] — The business relies on proprietary image analysis and implant design technology. - **Partner and personnel dependence** [medium] — Commercialization and development rely on specialized partners and key staff. - **Cybersecurity risk** [medium] — The company depends on IT systems for design, operations, and communication. - Regulatory approval risk can delay or block market entry - Clinical study outcomes affect adoption and reimbursement - IP protection is important for defending the technology - Reimbursement uncertainty can limit commercial uptake - Dependence on key personnel and partners increases execution risk - Cybersecurity and supply-chain disruptions can affect operations ## Accounting The main accounting judgment is capitalization and impairment of development expenditure, since Episurf is still building products that may only later generate economic benefits. Investors should also watch lease accounting, government grants, and any acquisition accounting or goodwill recognition, because these items can materially affect reported assets and expenses. - **Capitalized development expenditure** — Affects intangible assets, amortization, and reported operating expenses - **Intangible asset impairment** — Can create non-cash charges and reduce equity - **Lease accounting** — Affects EBITDA-like measures, depreciation, and leverage presentation - **Government grants** — Can reduce reported operating expenses in qualifying periods - **Acquisition accounting and goodwill** — Introduces valuation judgments and future impairment risk - Capitalized development costs depend on future benefit assessments - Intangible asset impairment risk is important for R&D-heavy assets - Lease accounting affects balance sheet liabilities and depreciation - Government grants can offset personnel costs in some periods - Acquisition accounting may create goodwill and valuation judgments --- *Last updated: 2026-08-11T04:04:52.056773+00:00*